Transcripts

Boston Scientific (BSX) earnings call transcripts

Earnings call transcripts for Boston Scientific, with a summary, the guidance given, and what analysts pressed on.

Open BSX in Gloom →
Boston Scientific's chart, financials and news, free in your browser.Open BSX in Gloom →
  • Q3 2026 earnings call

    Management framed 2026–27 as a downcycle led by EP and Watchman, with restructuring and launches intended to restore growth in 2028.

    Oct 28, 2026Cautious-0.38
  • Q2 2026 earnings call

    Management framed the quarter as solid but reset expectations after unexpectedly sharp Watchman market weakness and EP share losses, with recovery pushed toward 2028.

    Jul 29, 2026Cautious-0.25
  • Q1 2026 earnings call

    Management framed 2026 as more challenging than expected, citing EP share pressure, Watchman case mix and execution issues in urology.

    Apr 22, 2026Cautious-0.20
  • Q4 2025 earnings call

    Management framed 2026 growth as broad-based despite a slower EP market and temporary product disruptions, with confidence in its long-range goals unchanged.

    Feb 04, 2026Confident0.72